Attached files
file | filename |
---|---|
EX-31.1 - EX-31.1 - Medite Cancer Diagnostics, Inc. | c58222exv31w1.htm |
EX-23.1 - EX-23.1 - Medite Cancer Diagnostics, Inc. | c58222exv23w1.htm |
EX-10.28 - EX-10.28 - Medite Cancer Diagnostics, Inc. | c58222exv10w28.htm |
EX-10.27 - EX-10.27 - Medite Cancer Diagnostics, Inc. | c58222exv10w27.htm |
EX-10.25 - EX-10.25 - Medite Cancer Diagnostics, Inc. | c58222exv10w25.htm |
10-K - FORM 10-K - Medite Cancer Diagnostics, Inc. | c58222e10vk.htm |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Robert F. McCullough, Jr., the Chief Executive Officer and Chief Financial Officer of Cytocore,
Inc. (the Company), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18
U.S.C. Section 1350, that to the best of my knowledge:
(1) the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2009
(the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
Date: May 17, 2010 | /s/ Robert McCullough Jr. | |||
Robert McCullough Jr. | ||||
Chief Executive Officer and Chief Financial Officer |
||||